Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UP79
UPID:
ATS8_HUMAN
Alternative names:
METH-2; METH-8
Alternative UPACC:
Q9UP79; Q9NZS0
Background:
A disintegrin and metalloproteinase with thrombospondin motifs 8 (ADAMTS8), also known as METH-2 and METH-8, plays a crucial role in the regulation of angiogenesis, the process by which new blood vessels form from pre-existing vessels. Its anti-angiogenic properties suggest a pivotal function in controlling vascular growth and stability.
Therapeutic significance:
Understanding the role of ADAMTS8 could open doors to potential therapeutic strategies. Its ability to inhibit angiogenesis positions it as a target of interest in the development of treatments for diseases characterized by abnormal vessel growth, such as certain cancers and retinopathies.